Status: Recruiting
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.
Participants needed: 28
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Qian ChuUpdated: Oct 1, 2024Locations: 8
Eligibility criteria
Patients with histologically stage IIIB, IIIC, IV Pulmonary Sarcomatoid Carcinom... [+6]
Imaging (CT or MRI) showed tumor invasion of major vessels. hemoptysis ≥ 2.5 mL... [+14]